2026 Awards Now Open for Nominations!
The NMD4C Awards are back!
We’re proud to recognize outstanding achievements across the neuromuscular research community.
Nominations are open for:
- Early Career Biomedical Researcher of the Year
- Early Career Clinical Researcher of the Year
- Publication of the Year
To be eligible, nominees must be NMD4C members. Early career awards are open to researchers within five years of their first independent appointment (adjusted for eligible leaves). The Publication of the Year award is open to any career stage for first or last authors of articles published since November 2024.
Deadline: 15th of January 2026.
Learn More & Submit Your Nomination
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
